Connective Tissue Diseases clinical trials

The registry lists 192 studies for Connective Tissue Diseases across more than 10 countries. 57 are recruiting or about to start. 35 of them are mainly about Connective Tissue Diseases (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-09. Counting its 73 narrower conditions too, such as Arthritis, Rheumatoid: 16,534 studies, 3,253 open.

Get an email when these change. Save the Connective Tissue Diseases studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Watch these studies

See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your saved searches, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your saved searches. Stop any time.

Status

Completed: 84
Recruiting: 44
Status unknown: 21
Active, not recruiting: 14
Terminated: 12
Not yet recruiting: 9

Phase

Phase 2: 44
Phase 3: 33
Phase 4: 16
Phase 1: 16
Early Phase 1: 2

Where

United States: 95
France: 28
Germany: 28
China: 27
United Kingdom: 23
Poland: 22

Who runs them

National Center for Research Resources (NCRR) (15) · Viatris Innovation GmbH (4) · Eli Lilly and Company (4) · London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's (3) · Amgen (3) · Qilu Hospital of Shandong University (3) · Liquidia Technologies, Inc. (3) · Bristol-Myers Squibb (3)

What is being tested here

Drugs under test in Connective Tissue Diseases studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug	Open	Phase 3	All
Belimumab	3	2	3
Treprostinil	2	2	5
Cenerimod	1	3	4
Cyclophosphamide	1	0	3
Pirfenidone	1	0	2
Ralinepag	1	2	2
Telitacicept	1	0	2
Litifilimab	1	1	1
Methoxsalen	1	0	1
Fludarabine	1	0	1

Drug classes tested here Alkylating agents 1 open · Antimetabolites 1 open · Tyrosine kinase inhibitors (TKIs) 4 · JAK inhibitors 3 · Endothelin receptor antagonists 3

Coming up

15phase 3 studies under way

14studies finish main data collection within a year3 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Dec 2026A Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension · Phase 3 · United Therapeutics
Dec 2026A Research Study to Evaluate the Efficacy and Safety of Cenerimod in Subjects Suffering From Systemic Lupus Erythematosus · Phase 3 · Viatris Innovation GmbH
Mar 2027A Research Study to Evaluate the Effects of a New Oral Medicine Called Cenerimod in Adults With Systemic Lupus Erythematosus · Phase 3 · Viatris Innovation GmbH
Dec 2026LUpus Eritematoso Sistemico NETwork and Registry · Società Italiana di Allergologia, Asma e Immunologia Clinica
Dec 2026Clinical Features and Prognosis of Takayasu's Arteritis With Pulmonary Arteries Involvement · China-Japan Friendship Hospital
Jan 2027129 Xenon MRI as a Biomarker for Diagnosis and Response to Therapy in Pulmonary Arterial Hypertension (PAH) · Bastiaan Driehuys
Jan 2027Skin Autofluorescence Assessment of Advanced Glycation End Products in Rheumatic Diseases · Bursa City Hospital
Mar 2027The Genetics Navigator: Evaluating a Digital Platform for Genomics Health Services · Unity Health Toronto
Mar 2027Impact of Capillaroscopy in the Investigation of Diffuse Interstitial Pneumonias · University Hospital, Bordeaux
Mar 2027Undifferentiated Connective Tissue Disease Registry · Hospital for Special Surgery, New York

Who these studies take

Of the 44 Connective Tissue Diseases studies recruiting now, 30 (68%) set no upper age limit and 8 (18%) stop at 75 or younger. 5 (11%) take children under 18. 1 (2%) are for women only and 1 (2%) for men only; 6 (14%) take healthy volunteers.

Recruiting studies that take each age, of 44
Age	Women	Men
10	3 (7%)	3 (7%)
18	39 (89%)	39 (89%)
30	41 (93%)	40 (91%)
40	41 (93%)	40 (91%)
50	42 (95%)	43 (98%)
65	42 (95%)	43 (98%)
75	38 (86%)	39 (89%)
85	32 (73%)	33 (75%)

Across all 192 studies, recruiting or not: 33% stop at 75 or younger and 15% at 65; 26% take children; 5% are for women only and 2% for men only; 16% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Connective Tissue Diseases studies take

Of 14 phase 2 interventional studies under Connective Tissue Diseases, half reached primary completion within 34 months of starting, counting those still running.

Start to primary completion	Every sponsor	Industry	Non-industry
Phase 2	34 mo15–49 · 14 studies	—	—

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

Studies

Recruiting first, then most recently updated. Showing 50 of 192. Browse all 192 → or search them.